Market Overview
The global Live Biotherapeutic Products and Microbiome CDMO market provides contract development and manufacturing services for living microbial therapeutics and microbiome-based drugs. In 2025, the market is valued at approximately $78 million, reflecting a nascent but rapidly expanding segment within the broader biotherapeutics industry. As pharmaceutical developers outsource the complex manufacturing of these living products, CDMOs offer specialized fermentation, formulation, and clinical trial supply capabilities.
- •Market valued at approximately $78 million in 2025
- •Expected to reach between $159 million and $397 million by the late 2020s according to different industry projections
- •Represents a small but high-growth niche within the $481 billion global biotherapeutics market
Growth Drivers
The market is expanding rapidly due to increased R&D investment in microbiome therapeutics and the approval of live biotherapeutic products like SER-109 and Rebyota for recurrent Clostridioides difficile infection. Advances in strain isolation, genome sequencing, and Good Manufacturing Practice requirements for living organisms create demand for specialized CDMO expertise that many pharmaceutical companies lack internally.
- •Regulatory approvals of microbiome-based products validate commercial viability and attract further investment
- •Growing understanding of the human microbiome's role in health drives expanding discovery pipelines
- •Complex manufacturing requirements for live organisms necessitate specialized contract manufacturing partners
Segmentation and Regional Analysis
The market segments across service type, including strain banking, process development, clinical and commercial manufacturing, and by organism type, such as bacterial, yeast, and viral-based therapeutics. Geographically, North America dominates due to concentrated biotech activity and established FDA regulatory pathways, while Europe shows strong growth through academic-medical center partnerships.
- •Bacterial-based live biotherapeutic products represent the largest product category
- •North America accounts for the majority of market share, with Europe as the second-largest region
- •Clinical-stage development services currently comprise a larger portion of the market than commercial manufacturing
Trends and Outlook
What are the recent trends and outlook?
The market is expected to sustain strong double-digit growth as more live biotherapeutic candidates advance through clinical trials and seek regulatory approval. CDMOs are investing in anaerobic processing capabilities and closed-system manufacturing to maintain sterility and viability of living products, positioning the sector for continued expansion through 2030 and beyond.
- •Investment in anaerobic and GMP-compliant fermentation infrastructure is accelerating among major CDMOs
- •Continued FDA approvals of live microbial products will drive sustained demand for manufacturing partnerships
- •Industry consolidation is likely as larger CDMOs acquire specialized microbiome-focused manufacturers
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.